Vertex Pharmaceuticals is diversifying from its cystic fibrosis dominance into pain and other markets. Check out our recommendation for VRTX stock.

Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the new Donald Trump administration. Health care stocks can often be a solid defensive play in an uncertain economy.

Walmart's "everyday low prices" should attract customers even if a recession comes. Which group of individuals is in the best ...

Gene therapy and gene editing are on the cutting edge of modern biotechnology. Gene therapies are used to correct genetic abnormalities by introducing genetic material at a cellular level and ...

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target ...

Combination treatment with a GLP-1 agonist and thiazolidinedione in type 2 diabetes was tied to a significantly lower risk of ...

The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...